Skip to main content
. 2021 Jun 19;11(5):529–540. doi: 10.1016/j.jpha.2021.06.004

Fig. 3.

Fig. 3

Simplified representation of SARS-CoV-2 life cycle along potential drug targets. Arbidol, chloroquine, and hydroxychloroquine block membrane fusion or endocytosis. Lopinavir/ritonavir inhibits the proteolysis of translated peptide, whereas remdesivir targets RNA dependent RNA polymerase (RdRp) to inhibit SARS-CoV-2 protein generation. Immunomodulatory agents, sarilumab, and tocilizumab, target IL-6 receptor limit cytokine release. ACE2: angiotensin-converting enzyme-2; IL-6: interleukin-6.